Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
1 patent granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Lisata Therapeutics, Inc.’s names, not what it holds today.
Patents granted
1
1 utility, 1976 to Dec 31, 2025
Granted in 2025
1
in the last year the record reads
Applications published
13
2 of them in 2025
Names they are printed under
6
a former name, its own name
By yearGrantedApplications published
'06'10'11'12'14'15'16'22'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
NEOSTEM, INC. a former name
US, as the owner printed on each patent
5 publishedNEOSTEM, INC. a former name
named as the applicant on its applications, in US
4 publishedLISATA THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
2 publishedCALADRIUS BIOSCIENCES, INC. a former name
named as the applicant on its applications, in US
1 publishedCaladrius Biosciences, Inc. a former name
US, as the owner printed on each patent
1 publishedLISATA THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 16, 2025 | 2025/0320251 | PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES | Pharmaceuticals | LISATA THERAPEUTICS, INC. |
| May 8, 2025 | 2025/0144169 | iRGD-ANALOGS AND RELATED THERAPEUTIC METHODS | Pharmaceuticals | LISATA THERAPEUTICS, INC. |
| Jan 27, 2022 | 2022/0023345 | Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection | Pharmaceuticals | Caladrius Biosciences, Inc. |
| Sep 15, 2016 | 2016/0263163 | USES AND ISOLATION OF VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS | Pharmaceuticals | CALADRIUS BIOSCIENCES, INC. |
| Jan 28, 2016 | 2016/0022743 | HUMAN VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS FOR TREATMENT OF OCULAR DISEASE | Pharmaceuticals | NEOSTEM, INC. |
| Jan 14, 2016 | 2016/0008506 | STEM CELL COMPOSITIONS AND METHODS FOR WOULD HEALING | Pharmaceuticals | NEOSTEM, INC. |
| Apr 2, 2015 | 2015/0093447 | STEM CELL IDENTIFICATION AND PURIFICATION METHOD | Pharmaceuticals | NEOSTEM, INC. |
| Nov 20, 2014 | 2014/0341863 | ADULT MESENCHYMAL STEM CELL (MSC) COMPOSITIONS AND METHODS FOR PREPARING THE SAME | Biotechnology | NEOSTEM, INC. |
| Apr 24, 2014 | 2014/0112891 | AUTOLOGOUS HUMAN ADULT PLURIPOTENT VERY SMALL EMBRYONIC-LIKE (hVSEL) STEM CELL REGENERATION OF BONE AND CARTILAGE | Pharmaceuticals | NEOSTEM, INC. |
| Jul 26, 2012 | 2012/0189585 | METHOD AND COMPOSITION FOR RESTORATION OF AGE-RELATED TISSUE LOSS IN THE FACE OR SELECTED AREAS OF THE BODY | Pharmaceuticals | NEOSTEM, INC. |
What it applied for, 2024 to 2025: Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.